Document is current

Article History

First Online: 17 May 2018

Competing interests

: M.V.H. has received research grants from Boehringer Ingelheim, Bayer HealthCare and PfizerBristol-Myers Squibb. He has received consultancy and lecture fees from PfizerBristol-Myers Squibb, Boehringer Ingelheim, Bayer HealthCare and Aspen. S.V.K. has received consultancy and lecture honoraria from Bayer HealthCare, Boehringer Ingelheim, Daiichi-Sankyo and PfizerBristol-Myers Squibb, payment for travel accommodation and meeting expenses from Bayer HealthCare and institutional grants from Boehringer Ingelheim, Bayer HealthCare and Daiichi-Sankyo. S.B. has received payment for travel accommodation and meeting expenses from Daiichi-Sankyo and Bayer HealthCare. F.A.K. has received research grants from Bayer HealthCare, Bristol-Myers Squibb, Boehringer Ingelheim, MSD and Actelion and non-financial research support from Daiichi-Sankyo. P.H.R. is a founder of VarmX BV, holds equity in this company and acts as chief scientific officer. P.H.R. is also an inventor on patents for factor V Leiden and prothrombin G20210A, and his department receives royalties related to these patents. G.L.G. holds an Early Researcher Award from the Province of Ontario, a Canadian Pacific Has Heart and Stroke Foundation Cardiovascular Award and the Chair in Diagnosis of Venous Thromboembolism, Department of Medicine, University of Ottawa Faculty of Medicine. M.R. holds a Chair in Venous Thrombosis and Thrombophilia, Department of Medicine, University of Ottawa Faculty of Medicine and a Heart and Stroke Foundation of Ontario Career Scientist Award. A.V.N. is supported by the Netherlands Organisation for Scientific Research (NOW) Vici grant and has received research grants from Actelion, Pfizer and United Therapeutics. All other authors declare no competing interests.